ESTRO meets Asia 2024 - Abstract Book

S213

Interdisciplinary – Lung

ESTRO meets Asia 2024

and conventional fractionated radiotherapy groups. All of them were numerically higher in the hypofractionated radiotherapy group, and the difference for lung V10, lung V20 and MLD was significant. For G3P, ICI was not a risk factor, while interstitial lung abnormality (ILA) scores, DLCO, lung V5, lung V10 and MLD were significant predictors. We also developed an integrated predictive model for 6-month cumulative incidence of G2P incorporating fractionation schedule, MLD and ICI, with a concordance index of 0.744.

Conclusion:

Our findings revealed that hypofractionated radiotherapy, as opposed to conventional fractionated radiotherapy, was associated with a lower risk of G2P. ICI was independently related with the development of G2P but not G3P. We also validated the predictive value of lung dosimetric parameters, ILA scores and DLCO for pneumonitis. Furthermore, a predictive model for G2P was developed, which could aid in the clinical assessment of pneumonitis risk in patients with inoperable stage II-III NSCLC.

Keywords: hypofractionated radiotherapy, immunotherapy

References:

1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-50. 2. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-29. 3. Yegya-Raman N, Friedes C, Lee SH, Iocolano M, Duan L, Wang X, et al. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys. 2023. 4. Chen F, Niu J, Wang M, Zhu H, Guo Z. Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy. J Transl Med. 2023;21(1):368.

5. Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS, Ahn MJ, et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2020;146:23-9.

141

Digital Poster

Radiating Hope: Assessing the Utilization Rate of Radiotherapy in Lung Cancer Patients in Indonesia

Donald Arinanda Manuain, Gregorius Ben Prajogi, Tiara Bunga Mayang Permata, Handoko Handoko, Sri Mutya Sekarutami, Soehartati Gondhowiardjo

Department of Radiation Oncology, Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia

Purpose/Objective: